Learn more about Mirtazapine Oral Pharmacokinetic Data and Daily Dosing.
“Tell me how your cat behaves when he or she eats.”
“How would you describe your cat’s appetite?”
“Describe your cat’s eating behavior.”
“How many times a day does your cat visit the food bowl?”
“Describe your typical feeding routine with your cat.”
“Tell me how your cat’s eating habits have changed.”
For more information:
Contact your Dechra Representative or call (866) 683-0660.
To place an order now:
Contact your Dechra or Distributor Representative or call (866) 683-0660.
Mirataz is indicated for the management of weight loss in cats.
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information, click here.
US Patent 10,603,272
Mirataz® is a registered trademark of Dechra Ltd.